© Marek Kruszewski

Researchers from the Helmholtz Centre for Infection Research in Braunschweig and the Medical School Hannover have been awarded a prestigious grant from the Institute of Biomedical Translation to further advance their innovative first-in-class hemolysin inhibitors targeting Staphylococcus aureus. This funding will support the exploration of a second medical indication and aid in the preparation for launching a spinoff company.

And the good news doesn’t end there! The team has also secured a grant from the German Center for Infection Research (DZIF) to develop biomarkers aimed at enabling precise patient selection, further enhancing the potential impact of their groundbreaking research.

The Helmholtz Centre for infection Research together with the Lead Discovery Center (LDC), have developed small molecule-based inhibitors of alpha-hemolysin to treat lung infections caused by Staphylococcus aureus.

A post by Prof. Dr. Mark Brönstrup | HZI – Helmholtz-Zentrum für Infektionsforschung GmbH

Just like HZI | LDC, INCATE encourages all our ventures to share their exciting opportunities, connections, and milestones. We’d love to hear from you!
Reach out to us at comms@incate.net  and let us know what you’ve been up to.